MS Treatment, PTV News: Mar 18, 2010




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: MS Treatment, PTV News: Mar 18, 2010
Released on: March 18, 2010. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Company
GW Pharmaceuticals expects UK and Spain approval for marijuana extract
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
GW Pharmaceuticals
GW Pharmaceuticals is a pharmaceutical firm developing a portfolio of cannabinoid medicines, of which the lead product is Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain and neuropathic pain.
Almirall
Almirall is an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain. The company researches, develops, manufactures and commercializes its own R&D and licensed drugs with the aim of improving people's health and wellbeing. The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD(Chronic Obstructive Pulmonary Disease, rheumatoid arthritis, multiple sclerosis, psoriasis and other dermatology indications. Almirall's products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 11 affiliates.